Open AccessA pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.
Author(s) -
Rosa María Lidón,
Pierre Théroux,
Jacques Lespérance,
Burt Adelman,
R Bonan,
Damien Duval,
J. Lévesque
Publication year - 1994
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.89.4.1567
Subject(s) - medicine , streptokinase , timi , myocardial infarction , thrombolysis , heparin , direct thrombin inhibitor , cardiology , anesthesia , surgery , atrial fibrillation , warfarin , dabigatran
The success of streptokinase in acute myocardial infarction is hampered by the high failure rate to achieve early reperfusion. This study evaluates the possible benefit of Hirulog (Biogen, Cambridge, Mass), a direct thrombin inhibitor, as adjunct therapy to streptokinase to enhance early patency and prevent rethrombosis. Heparin has been shown to be of very limited benefits in this setting.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom